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It is well known that inducible nitric oxide synthase (iNOS) is a major effector of innate immune signaling. 8 Activation of innate immunity leads to NFκB (nuclear factor kappa B)-mediated expression of iNOS, 9 which S-nitrosylates proteins to affect their activity and cellular location. 10 Accordingly, we hypothesized that innate immune activation of iNOS and S-nitrosylation of epigenetic modifiers might contribute to epigenetic plasticity required for transdifferentiation. Driven by this hypothesis, we now describe the discovery of a novel iNOS-dependent post-translational modification of the repressive epigenetic machinery to facilitate transdifferentiation.
Methods
Chemicals and Reagents
All chemicals were purchased from Sigma-Aldrich (St Louis, MO) unless otherwise stated. Other reagents included fetal bovine serum, Taqman real-time polymerase chain reaction (RT-PCR) primers, Taqman master mix, 4-amino-5-methylamino-2′, 7′-difluorofluorescein diacetate), RNAimax, and 4'6-diamidino-2-phenylindole (DAPI) (Life Technologies, Carlsbad, CA); polyinosinic:polycytidylic acid (PIC) and NFκB inhibitors Bay117082, celastrol, and dexamethasone (Invivogen, San Diego, CA); antibody against the S-nitroso (SNO) moiety (SigmaAldrich); antibody against 3-nitrotyrosine (NT; Cayman Chemical, Ann Arbor, MI); PE antibody against human CD31 and APC antibody against mouse CD144 (BD Biosciences, San Jose, CA); antibody against iNOS, HRP-conjugated goat anti-mouse or rabbit antibodies (Santa Cruz Biotechnology, Santa Cruz, CA); antibody against β-tubulin, ring finger protein 1A (RING1A), H3K27 trimethylation (H3K27me3) and H3K9 dimethylation (H3K9me2; Abcam, Cambridge, United Kingdom); bone morphogenetic protein-4, vascular endothelial growth factor, and basic fibroblast growth factor (Peprotech, Rocky Hill, NJ); and Scramble and iNOS siRNA (Integrated DNA Technologies, Coralville, IA).
Cell Culture and Induce Endothelial Cell Generation
BJ human neonatal foreskin fibroblast cells (BJ fibroblasts; Stemgent), wild-type (WT) and iNOS −/− murine embryonic fibroblasts (MEFs; Cell Biologics Inc, Chicago, IL) were cultured and maintained in Dulbecco modified Eagle's medium (Invitrogen) with 10% fetal bovine serum and 1% penicillin/streptomycin (5% CO 2 , 37°C). We transdifferentiated human and mouse fibroblasts to induce endothelial cells (iECs) using our previously established protocol. 7 Briefly, cells were treated with PIC (30 ng/mL) daily for 7 days, and the medium was gradually transitioned to a 10% knockout serum replacement. Cells were treated with endothelial cell growth medium 2 (-2; Lonza) containing 20 ng/mL bone morphogenetic protein-4, 50 ng/ mL vascular endothelial growth factor, and 20 ng/mL basic fibroblast growth factor for another 7 days. For maintenance of transdifferentiation, the cells were cultured for another 2 weeks in the presence of basic fibroblast growth factor, vascular endothelial growth factor, and 0.1 mmol/L 8-bromoadenosine-3′:5′-cyclic monophosphate sodium salt , with the medium changed every 2 days. In some experiments, inhibitors of iNOS or NFκB were present throughout the transdifferentiation protocol; they were readded when the transdifferentiation medium was refreshed.
RNA Extraction and Real-Time PCR
mRNAs were extracted from cultured cells and reverse transcribed into cDNA, and then specific primers for targeted genes were used for PCR amplification. For real-time PCR, a SYBR-green PCR system or Taqman system was used and ran on QuantStudio real-time PCR system from Life Technologies. Gene expression data using the ΔΔCt method was normalized to the expression of the 18S gene and plotted as relative fold changes.
Western Blot and Immunoprecipitation
Western blot analysis was performed as previously described. 6 Immunoprecipitation was performed using the Pierce Classic Magnetic IP/Co-IP Kit (Thermo Scientific, Waltham, MA) following manufacturer's manual.
Chromatin Immunoprecipitation-qPCR
Chromatin immunoprecipitation was performed using a previously established method. 6, 7 Recovery of genomic DNA was calculated as the ratio of copy numbers in the immunoprecipitate to the input control. Primers of the CD144 promoter were custom designed and synthesized from IDT as follows: primer sequence (5′-3′), (F): CAGCCTCTTGGTTCTTCTGG; (R): GGAGTCAAGTGACCCAGCTC.
Fluorescent Assay for Nitric Oxide
BJ fibroblasts were stained with DAF-FM DA to access intracellular nitric oxide (NO). Cultured cells exposed to different experimental conditions were incubated with DAF-FM DA 10 µmol/L at 37°C for 30 minutes. Fluorescence was quantified by measuring fluorescence intensity at 495 nm excitation and 515 nm emission by a fluorescence plate reader (Tecan M1000 PRO).
Immunofluorescent Staining
After BJ fibroblasts were cultured in 8-well chamber slides and exposed to experimental conditions, cells were fixed, permeabilized, blocked with 5% normal donkey serum, and stained for RING1A and iNOS. The nuclei were stained with DAPI for 10 minutes.
Analysis of S-Nitrosylation by Mass Spectrometry
Protein from both control and PIC-treated BJ fibroblasts was immunoprecipated using RING1A antibody, resolved on 4% to 12% gradient SDS/PAGE gel and stained with Coomassie Blue. After destaining, the RING1A band was cut and sent to the mass spectrometry-proteomics core facility (Baylor College of Medicine) for mass spectrometry (MS) analysis. The gel band was further destained and double digested with trypsin and GluC in situ. Peptides in the gel were extracted, quantified and 200 ng of each sample was analyzed using the Eksigent nanoLC system and then the ABCIEX TripleTOF 5600 mass spectrometer. The Ekisgent nanoLC and the ABCIEX TripleTOF 5600 mass spectrometer were controlled by Analyst software version 1.6 (ABCIEX Inc). The MS spectra (m/z 100-2000) were acquired with internal mass calibration. Raw data were converted to MGF format and then imported into Peaks software v6.0 for further peak generation and database search with the SPIDER function. The search sequence was E3 ubiquitin-protein ligase RING1A of human (NP_002922.2 GI:51479192).
Construction of RING1A Overexpression Plasmid and Site-Directed Mutagenesis
The human RING1A cDNA fragment was amplified with forward primer (5′-CAGGAATTCGAATGACGACGCCGGCGAATG-3′) and reverse primer (5′-GAGGTCGACGTCACTTTGGATCCTTGG TGGGAGC-3′) from pCMV6-XL4-RING1A (OriGene, SC118280) and ligated into EcoRI/SalI digested pCMV-Tag2C to generate pCMVTag2C-RING1A. We further created pCMV-Tag2C-RING1A-C398A using a PCR-based method. 11, 12 Briefly, PCR reaction was performed using primer pair: C398A Mutation-Forward (5′-CGGCCACTG GAGCTGGCCTATGCTCCCACCAAGGATCCAAAG-3′) and C398A Mutation-Reverse (5′-TTGGTGGGAGCATAGGCCAGCTCCAGTGG CCGGGACAC-3′). The PCR products were treated with DpnI and transformed into Escherichia coli Top10 competent cells by heat shock. Single clones were sequenced to examine the C398A mutation.
Flow Cytometry
Cells were trypsinized and filtered through a 40-µm nylon mesh to generate single-cell suspensions. Cells were stained with antibody for cell surface marker detection. Data were analyzed by flowjo software.
Data Analysis
Results are expressed as the mean±SEM. Statistical comparisons between 2 groups were performed via Student t test. One-way ANOVA was used to compare the means of multiple groups. P<0.05 was considered statistically significant.
Results iNOS Is Induced During Transdifferentiation
Our laboratory has previously established a nonviral methodology to transdifferentiate fibroblasts to iECs. 7 We activate innate immunity with a toll-like receptor 3 agonist PIC to induce epigenetic plasticity. In this state of epigenetic plasticity, fibroblasts are exposed to a media containing endothelial cytokines and small molecules that favor endothelial phenotype. The iECs that we obtain using this protocol are highly similar to human dermal microvascular endothelial cells as assessed by immunohistochemical markers, acetylated lowdensity lipoprotein uptake, the generation of capillary-like networks in matrigel, the generation of NO, and angiogenic cytokines and by RNAseq analysis. 7 We examined NOS gene expression at days 0, 6, 14, 21, and 28; by day 28 of the transdifferentiation protocol, CD31+ iECs can be detected, as quantified by FACS analysis ( Figure  1A and 1B). We observed that the expression of iNOS increased throughout transdifferentiation, peaking at day 21 ( Figure 1C ). By contrast, the expression of eNOS (endothelial NOS) was not detectable until day 28 when there was evidence of transdifferentiation to a mature endothelial cell phenotype ( Figure 1D ). Throughout the whole process, nNOS (neuronal NOS) was not detectable (data not shown).
NO Is Generated During Transdifferentiation
To determine whether the upregulation of iNOS expression increased the generation of NO, we used DAF-FM DA staining. DAF-FM DA is essentially nonfluorescent until it reacts with NO to form a fluorescent benzotriazole. 13 On day 3 of the transdifferentiation protocol, we observed a significant increase in DAF-FM DA fluorescence in both image analysis ( Figure 2A 
Transdifferentiation Requires iNOS Induction and NO Generation
To determine whether generation of NO is required for transdifferentiation, we performed the transdifferentiation studies in the presence of the NOS inhibitor l-NAME or in the presence of NO scavengers uric acid or ebselen. Each of these agents substantially reduced transdifferentiation, as assessed at day 28 by FACS for CD31 + iECs ( Figure 3A and 3C). This indicates that NO generation is required for efficient transdifferentiation. 
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We hypothesized that by inhibiting NFκB activity, we would suppress the induction of iNOS and thereby reduce the efficiency of transdifferentiation. Indeed an inhibitor of NFκB activity, Bay117082, decreased iNOS gene expression ( Figure 3D ) and reduced the yield of iECs ( Figure 3B and 3C). Two other known antagonists of NFκB-mediated iNOS induction, celastrol, and dexamethasone also reduced the yield of iECs by 90% ( Figure 3B and 3C ). These studies confirm that NFκB-mediated induction of iNOS is required for effective transdifferentiation.
Genetic Deficiency of iNOS Abolishes Transdifferentiation
To further test the role of iNOS in transdifferentiation, we assessed the transdifferentiation of WT and iNOS −/− MEFs to iECs. We confirmed the increasing expression of iNOS during transdifferentiation in WT MEF at days 0, 3, and 14 ( Figure 4C ), whereas iNOS gene expression was not detected in iNOS −/− MEF. We observed that transdifferentiation was nearly abolished in the iNOS −/− MEF. To confirm this work in human cells, we knocked down iNOS in BJ fibroblasts by siRNA ( Figure 4D ). This knockdown of iNOS substantially reduced the yield of iECs ( Figure 4E ). The effect of siRNA knockdown was reversed by iNOS overexpression using a pcDNA3.1-his-iNOS plasmid 14 ( Figure 4E ). These data suggest that iNOS is required for transdifferentiation.
RING1A Is S-Nitrosylated During Transdifferentiation
Our data indicated that the NFκB-iNOS-NO pathway is required for transdifferentiation. We were interested to know whether this pathway exerted its effect on transdifferentiation by post-translational modification of epigenetic modifiers, so as to enhance epigenetic plasticity. Because NO species may react with cysteine to form SNO proteins, and peroxynitrite can react with l-tyrosine to form 3-nitro-l-tyrosine (3-NT), we quantified SNO and 3-NT containing proteins as an index of iNOS activity. As shown in western analysis, cell lysate protein SNO ( Figure 5A ) and 3-NT levels are significantly increased as early as day 3 after the induction of transdifferentiation (Online Figure I) .
It has been previously reported that HDAC2, RING1A, and CBX1 can be S-nitrosylated.
15-18 Accordingly, we turned our attention to detecting S-nitrosylation of epigenetic modifiers focusing first on HDAC2, RING1A, and CBX1. We observed that RING1A was SNO modified at day 3 during transdifferentiation ( Figure 5B ), but not HDAC2 or CBX1 (Online Figure II) . We confirmed the RING1A S-nitrosylation by immunoprecipitation of RING1A, followed by probing with SNO antibody. We found that in PIC-treated BJ fibroblasts RING1A was S-nitrosylated ( Figure 5C ). Consistent with our hypothesis, NFκB inhibitor Bay117082 could block this S-nitrosylation ( Figure 5C ), suggesting that NFκB-iNOS pathway is upstream of RING1A S-nitrosylation.
To identify the specific cysteine that is S-nitrosylated, we performed MS analysis of the RING1A immunoprecipitated from cell lysate of fibroblasts treated with vehicle or PIC. The MS studies revealed cysteine at 398 position is heavily S-nitrosylated ( Figure 6A ) by PIC stimulation. In addition, nitroso-cysteine modifications could also be detected in 279 and 332 position cysteines, although the modification level is low (Online Figure III) .
To further examine whether S-nitrosylation of RING1A at 398 cysteine is critical for transdifferentiation, we performed site-directed mutagenesis. We first constructed plasmids containing wild-type (pCMV-Tag2C-RING1A) or mutant RING1A (C398A mutation, pCMV-Tag2C-RING1A-C398A plasmid). The GCC codon encoding the 398 position cysteine was mutated into a TGC codon-encoding alanine, which we confirmed by sequencing ( Figure 6B ). Then both plasmids were transfected into BJ fibroblasts, which were then subjected to the transdifferentiation protocol with or without PIC. As shown in Figure 6C , C398A-RING1A is minimally S-nitrosylated after PIC, suggesting that the 398 position cysteine is the major site of S-nitrosylation. Subsequently, we assessed the effect of overexpression of the mutant RING1A on transdifferentiation. Fibroblasts-overexpressing C398A-RING1A were resistant to transdifferentiation ( Figure 6D ), by comparison to fibroblasts overexpressing the wild-type form of RING1A. Altogether, these data suggest that S-nitrosylation of RING1A at 398 cysteine is critical for transdifferentiation.
iNOS Translocates to the Nucleus and Binds RING1A
A recent study indicates that iNOS may bind to its protein target, providing some specificity of S-nitrosylation.
14 To determine whether iNOS physically associates with RING1A, we immunoprecipitated RING1A and probed for iNOS ( Figure 5D ). These experiments indicated that iNOS does bind to RING1A. Furthermore, we examined the cellular localization of iNOS and RING1A. Under basal conditions, iNOS was primarily observed in the cytoplasm. After PIC treatment, we observed iNOS translocated to the perinuclear and nuclear region. Colocalization of iNOS and RING1A in the nucleus (Figure 7) can also be detected. A physical association of iNOS with the epigenetic modifier RING1A could provide for specificity of the RING1A-SNO modification.
RING1A Nitrosylation Reduces Its Chromatin Binding and Suppressive Chromatin Marks in Endothelial Promoters
RING1A is a critical component of polycomb repressive complex (PRC) 1 and is required for stabilizing repressive epigenetic marks, such as H3K27 trimethylation (H3K27me3). 19, 20 To examine whether the SNO modification of RING1A has any impact on cellular H3K27me3 level, we performed Western blot and found that cellular H3K27me3 levels were decreased in PIC-treated cells. This effect of PIC was abrogated by using an NFκB inhibitor Bay117082 to block iNOS induction ( Figure 8A ). This result suggested that the RING1A-SNO modification may destabilize the PRC complex to reduce H3K27 trimethylation.
To confirm that SNO modification of RING1A impairs its binding to chromatin, and thereby reduces H3K27me3, we used chromatin immunoprecipitation assay. Specifically, we examined the promoter region of CD144, an endothelialspecific gene that is fully repressed in fibroblasts. After PIC treatment for 3 days, RING1A binding to CD144 promoter is decreased ( Figure 8B ) together with decreased levels of H3K27me3 ( Figure 8C ). In addition, H3K9me2 is also decreased in the CD144 promoter ( Figure 8D ). These studies are consistent with a functional effect of S-nitrosylation to reduce RING1A association with the chromatin and thereby to decrease the suppressing histone marks at promoters of endothelial genes during transdifferentiation.
Discussion
A Novel Mechanism Underpinning Transdifferentiation
The new and salient findings of this article are that (1) during transdifferentiation of fibroblasts to endothelial cells, the expression of iNOS is induced, and NO is generated; (2) the generation of NO is required for efficient transdifferentiation; (3) NO facilitates transdifferentiation, in part, by blocking repressive epigenetic markings; (4) this effect is achieved at least, in part, by iNOS binding to and nitrosylating RING1A, and (5) the S-nitrosylation of RING1A causes it to dissociate from the chromatin, impairing the ability of the PRC to maintain H3K27 trimethylation. Most importantly, we have identified a critical role for NO in transdifferentiation. Our results indicate that iNOS serves as an S-nitrosylase that directly binds to an epigenetic modifier to regulate chromatin remodeling during transdifferentiation. The temporal and spatial characteristics of the S-nitrosylation may provide the specificity of the epigenetic effect. We have previously shown that innate immunity is required for efficient nuclear reprogramming. 6 This is the first demonstration that NO generated during innate immune signaling regulates epigenetic plasticity.
These observations significantly extend our previous work, which revealed that innate immune activation is required for cellular metamorphoses. Specifically, we showed previously that toll-like receptor 3 stimulation facilitates nuclear reprogramming of human fibroblasts to iPSCs 6 or their transdifferentiation into endothelial cells. 7 We found that toll-like receptor 3 stimulation by PIC increased the expression of histone acetyltransferase family members and reduced the expression of HDAC family members and Dot1L. These changes would be expected to increase epigenetic plasticity, 21, 22 an expectation that was confirmed by chromatin immunoprecipitation-qPCR studies of the relevant promoter regions.
6,7 iNOS Is an Effector of Innate Immunity and Epigenetic Plasticity
Innate immune activation of NFκB induces iNOS expression. 23, 24 Subsequently, iNOS generates NO, which can activate guanylate cyclase to produce the second messenger cGMP. In addition, NO may S-nitrosylate cysteine residues of proteins to modify their function. 25 For example, S-nitrosylation of caspase 3 regulates apoptosis. 26 Others have shown that S-nitrosylation of the epigenetic modifier HDAC2 in embryonic cortical neurons regulates dendritic growth and branching. 15 In addition, iNOS has been reported to translocate into the nucleus both in malignant 27 and normal cells, 28, 29 but the biological implications of this translocation are obscure. Some epigenetic modifiers have been shown to be capable of S-nitrosylation in screening assays, [16] [17] [18] including RING1A and CBX1. However, it is not known whether these proteins are post-translationally modified in cells and whether the modifications modulate their function.
Thus, we hypothesized that iNOS-derived NO is a major effector of innate immunity in transdifferentiation. We found that iNOS is indeed upregulated during transdifferentiation (Figure 1 ) in association with increases in intracellular NO ( Figure 2 ) and with increased generation of SNO-NT ( Figure 5A ) and 3-NT modifications of cellular proteins (Online Figure I) . Notably, pharmacological antagonists that reduced intracellular NO levels consistently diminished transdifferentiation efficiency ( Figure 3A) . Furthermore, inhibitors of NFκB blocked the upregulation of iNOS, reduced NO levels, and also impaired transdifferentiation efficiency ( Figure 3B and 3D ). Together these studies indicated that iN-OS-generated NO is critical for transdifferentiation.
To further confirm iNOS is required for effective transdifferentiation, we derived MEFs from iNOS − /− mice. 30 These mice have a knockout of the iNOS calmodulin-binding Figure 4E ). Taken together, the genetic and pharmacological studies suggest that iNOS-generated NO is required for transdifferentiation.
Nitrosylation of RING1A Is Required for Transdifferentiation
Next, we screened several epigenetic modifiers that have been reported to be S-nitrosylated. Of these, only RING1A is heavily S-nitrosylated at the 398 position cysteine during innate immune activation as assessed by MS ( Figure 6A ) and Co-IP studies ( Figure 5 ). The S-nitrosylation of a protein can be achieved through several different mechanisms. 10, 25, 31, 32 Recently, it has been shown that protein S-nitrosylation can be achieved in a target-selective manner at a sequence motif recognition site by an inducible heterotrimeric S-nitrosylase complex.
14 This protein complex consists of iNOS, S100A8, and S100A9 and recognizes a conserved I/L-X-C-X 2 -D/E motif. Of note, although RING1A lacks this motif, our Co-IP data indicate that iNOS associates with and S-nitrosylates RING1A ( Figure 5D ). Immunostaining also confirms the colocalization of iNOS and RING1A in the nucleus (Figure 7 ). This physical association is likely to provide some specificity of the S-nitrosylation. Indeed, we were not able to rescue the transdifferentiation process in iNOS −/− MEFs using the NO donor SIN1 (data not shown). These experimental results indicate a critical role of the physical association of iNOS with RING1A for transdifferentiation.
RING1A is a major component of the PRC1, 33 which acts as a transcriptional repressor. 34 A sequential recruitment of PRC2-PRC1 has been described, 35, 36 in that PRC1 recognizes the H3K27me3 marker that is imposed by PRC2. [37] [38] [39] [40] Maintenance of H3K27 trimethylation requires PRC1-induced H2A monoubiquitination. 19, 20 Knockout of RING1A reduces H3K27me3 marks. 34 In this regard, we observed that PIC reduced binding of RING1A to, and H3K27 trimethylation of, the endothelial-specific gene promoter CD144 ( Figure 8B and 8C). These observations suggest that when RING1A is S-nitrosylated, it dissociates from the chromatin, thereby releasing the PRC complex and destabilizing repressive marks, such as H3K27me3.
Physiological and Pathobiological Relevance of Our Findings
iNOS is a potent cellular defense mechanism, generating reactive nitrogen species that also have cytotoxic effects. We now reveal another role for iNOS in innate immunity, as a facilitator of epigenetic plasticity and phenotypic fluidity. This too may be an important mechanism for cellular defense because phenotypic fluidity in the face of pathogens or damage may provide a survival advantage.
In some instances, the epigenetic plasticity associated with innate immune activation may have a physiological role. For example, in the setting of experimental myocardial infarction, a substantial number of cardiac fibroblasts may transdifferentiate to endothelial cells to enhance the angiogenic response to ischemic injury. 41 Epigenetic plasticity induced by innate immunity might also participate in pathological transdifferentiation. For example, the chronic inflammation associated with gastroesophageal reflux disease is accompanied by a premalignant transdifferentiation of the stratified squamous esophageal epithelium to a columnar epithelium reminiscent of the small intestine. 42 Indeed, it has been long recognized by clinicians that cancers may arise in the setting of chronic inflammation or infection. 43, 44 Furthermore, iNOS is often expressed in premalignant states and in cancer. [45] [46] [47] [48] An understanding of the role by which chronic inflammation leads to epigenetic plasticity may provide a therapeutic avenue in the prevention of cancer. Strategies for direct reprogramming of somatic cells may be enhanced by insights into the mechanisms by which innate immune signaling drives epigenetic plasticity.
Conclusions
We have identified a novel mechanism by which innate immune signaling facilitates transdifferentiation. The activation of iNOS and the generation of NO are associated with iNOS binding to, and S-nitrosylating RING1A. This modification causes a dissociation of RING1A from the chromatin. This effect is associated with a reduction in H3K27 trimethylation, a repressive chromatin marking. These effects would be predicted to increase the probability of an open configuration of the chromatin and thereby facilitate transdifferentiation. These insights have relevance to cancer biology in that pathological transformation frequently occurs in the setting of chronic inflammation. Our work also has relevance to cardiovascular regeneration, given the importance of physiological transdifferentiation in the response to injury.
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